Abstract
Despite being a highly successful chemotherapeutic drug, doxorubicin (DOX) has several significant disadvantages. Therefore, there is a drive to create novel medication combinations and different modes of delivery of the anticancer drug. Here, we outline a strategy for DOX photorelease, utilizing a photolabile precursor ruthenium complex [Ru(bpy)2Cl2] 1 to develop the light-activated prodrug [Ru(bpy)2DOX](PF6)22. The DOX complex is stable in the dark but releases DOX when exposed to visible light.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
